Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STSA 1002

Drug Profile

STSA 1002

Alternative Names: STSA-1002

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Staidson Beijing BioPharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Adult respiratory distress syndrome
  • Phase I SARS-CoV-2 acute respiratory disease; Vasculitis

Most Recent Events

  • 26 Mar 2024 Staidson (Beijing) Biopharmaceuticals terminates a phase I trial in healthy volunteers (In combination therapy) in China due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project (IV) (NCT05559125)
  • 09 Dec 2023 Phase-I/II clinical trials in Adult respiratory distress syndrome in China (IV) (NCT06038916)
  • 15 Sep 2023 Staidson Beijing Biopharmaceuticals plans a phase Ib/II trial for Acute Respiratory Distress Syndrome in China (Injection) (NCT06038916)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top